Omalizumab in chronic urticaria: a retrospective series of 15 cases
- 1 May 2013
- journal article
- therapeutic hotline
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 26 (3), 257-259
- https://doi.org/10.1111/j.1529-8019.2013.01549.x
Abstract
Omalizumab is a monoclonal anti-IgE antibody approved for the treatment of severe allergic asthma. There is increasing evidence in the literature of its usefulness in chronic urticaria. Herein, we report a retrospective case series of 15 patients with chronic idiopathic urticaria treated with omalizumab. We reviewed their medical records to assess the improvement achieved after 3 and 6 months of treatment. Complete response was defined as symptom disappearance that could be followed by discontinuation of antihistamines, and partial response as symptom improvement, but with symptom worsening when attempting to discontinue antihistamines. After 3 months of treatment, 12 patients responded, with partial response in 9 and complete response in 3. At 6 months, 8 of 10 patients continuing on omalizumab had a complete response and 2 a partial response. The results of the present retrospective series show the effectiveness of omalizumab in most treated patients, which is consistent with other recently published series and studies. These data support its role in the management of patients with chronic urticaria refractory to conventional treatments.Keywords
This publication has 5 references indexed in Scilit:
- A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 2011
- Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidaseJournal of Allergy and Clinical Immunology, 2011
- Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumabClinical and Molecular Allergy, 2011
- EAACI/GA²LEN/EDF/WAO guideline: management of urticariaAllergy, 2009
- Treatment of chronic autoimmune urticaria with omalizumabJournal of Allergy and Clinical Immunology, 2008